Drugs News and Research

RSS

Isis Pharmaceuticals adds ISIS-APOCIIIRx to its development pipeline to treat TG

Isis Pharmaceuticals, Inc. announced today that it has added a new drug, ISIS-APOCIIIRx, to its development pipeline. ISIS-APOCIIIRx provides a novel approach to treat hypertriglyceridemia, or high levels of triglycerides (TG).

12 Jan 2010

AHF to host protest targeting Merck over the steep price for its key HIV/AIDS drug, Isentress

AIDS Healthcare Foundation (AHF) will host a protest Tuesday, January 12, at 10:30am targeting Merck and Co. Pharmaceuticals over the steep price for its key HIV/AIDS drug, Isentress, during the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

12 Jan 2010

Experiments show Alzheimer's drug may halt the growth of oesophageal cancer

Cancer of the gullet, or oesophagus, is one of the ten most common cancers in the Western world, and there have been recent alarming increases in the number of cases each year in the US and UK.

12 Jan 2010

Idenix Pharmaceuticals announces significant progress in HCV development programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced significant progress in three HCV programs

12 Jan 2010

PDGFR's role in new blood vessel formation may explain cardiovascular side effects

A growth factor that is a common target of cancer drugs also plays an important role in the heart's response to stress, researchers at The University of Texas M. D. Anderson Cancer Center report online this week in the Journal of Clinical Investigation.

12 Jan 2010

Detroit paper explores pain of facing breast cancer without insurance

A woman with a $7,000 annual income and $67 in the bank was diagnosed with breast cancer, leading to a week of phone calls from her surgeon to state, federal and hospital officials before a charitable agreement was struck with a medical center, the Detroit Free Press reports.

12 Jan 2010

Targacept signs collaboration and license agreement with AstraZeneca

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that its collaboration and license agreement with AstraZeneca for the global development and commercialization of TC-5214 for major depressive disorder (MDD) has become effective as a result of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

11 Jan 2010

NIH renews grant to continue cell growth regulation research

The new year began on a high note for Alan Leonard and Julia Grimwade, professors of biological sciences at Florida Institute of Technology, when they learned their National Institutes of Health grant, which they have held for the last 11 years, had been renewed for four more years. The competitive renewal brings them $1,024, 944 to continue their research into the regulation of cell growth and division.

11 Jan 2010

Lives of 400 Swedes can be saved annually if side effects of pharmaceuticals prevented

A scientific study indicates that the lives of 400 Swedes could be saved annually if measures were taken to prevent side effects of pharmaceuticals. Now these researchers in Sweden, at the Nordic School of Public Health (NHV) and elsewhere, have reviewed randomly selected deaths in three Swedish counties and found that 14 percent of these deaths could have been avoided if a drug had been replaced or if the dosage had been lowered.

11 Jan 2010

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

SRI International Dedicates New Tampa Bay Research Facility SRI International, one of the world's leading independent research and technology development organizations, officially opened its new 40,000-square-foot research facility located at the Port of St. Petersburg.

11 Jan 2010

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Mirna Therapeutics announced today that the Company received a $5 million award from the State of Texas through the Texas Emerging Technology Fund (“ETF”). The ETF was created with the goal of growing new and existing businesses to accelerate the introduction of new products and services in the marketplace. This is the largest award of this type that has ever been granted.

11 Jan 2010

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Meda has in-licensed exclusive rights to Ceplene (histamine dihydrochloride) from EpiCept Corporation, a US-based biopharmaceutical company.

11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

Common brain tumour in children can arise from stem cells

New research from scientists at Queen Mary, University of London shows how the most common type of children's brain cancer can arise from stem cells.

11 Jan 2010

Autism spectrum disorders result from miswiring of connections in developing brain

Studying a rare disorder known as tuberous sclerosis complex (TSC), researchers at Children's Hospital Boston add to a growing body of evidence suggesting that autism spectrum disorders, which affect 25 to 50 percent of TSC patients, result from a miswiring of connections in the developing brain, leading to improper information flow.

10 Jan 2010

Highmark joins with CDC to promote National Influenza Vaccination Week

Beginning Sunday, Jan. 10 and continuing through the week, Highmark Inc. will join with the Centers for Disease Control (CDC) to promote National Influenza Vaccination Week.

10 Jan 2010

Research into "chemical chaperone" may lead to new treatments for heart attacks

Researchers at the Indiana University and Stanford University schools of medicine have determined how a "chemical chaperone" does its job in the body, which could lead to a new class of drugs to help reduce the muscle damage caused by heart attacks.

10 Jan 2010

Thirteen percent of poison exposure calls related to painkillers

U.S. poison centers answered more than 4.3 million calls in 2008, including nearly 2.5 million calls about human exposures to poison, according to the American Association of Poison Control Centers -- up from 4.2 million calls in 2007.

9 Jan 2010

NOTA questions FDA's attempted regulation of on-site tests

The National On-site Testing Associates, Inc. (NOTA) has been revived in response to an attempt by the federal Food and Drug Administration (FDA) to regulate on-site, or point of collection, oral fluids drug and alcohol tests used by many small employers for non-medical purposes. NOTA is an association of manufacturers, users, and distributors of on-site drugs of abuse tests. These tests are sold throughout the world for use in workplace, sports, school, insurance, and criminal justice settings and numerous other non-medical applications. These tests are safe, accurate, cost effective, and easy to use.

9 Jan 2010

The Jean Coutu Group reports financial results for third-quarter of fiscal year 2010

The Jean Coutu Group (PJC) Inc. (the "Company" or the "Jean Coutu Group") reported its financial results today for the third quarter of fiscal year 2010 ended November 28, 2009.

9 Jan 2010

Drugs News and Research

Isis Pharmaceuticals adds ISIS-APOCIIIRx to its development pipeline to treat TG

AHF to host protest targeting Merck over the steep price for its key HIV/AIDS drug, Isentress

Experiments show Alzheimer's drug may halt the growth of oesophageal cancer

Idenix Pharmaceuticals announces significant progress in HCV development programs

PDGFR's role in new blood vessel formation may explain cardiovascular side effects

Detroit paper explores pain of facing breast cancer without insurance

Targacept signs collaboration and license agreement with AstraZeneca

NIH renews grant to continue cell growth regulation research

Lives of 400 Swedes can be saved annually if side effects of pharmaceuticals prevented

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Common brain tumour in children can arise from stem cells

Autism spectrum disorders result from miswiring of connections in developing brain

Highmark joins with CDC to promote National Influenza Vaccination Week

Research into "chemical chaperone" may lead to new treatments for heart attacks

Thirteen percent of poison exposure calls related to painkillers

NOTA questions FDA's attempted regulation of on-site tests

The Jean Coutu Group reports financial results for third-quarter of fiscal year 2010

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News